NASDAQ:PSTV

Plus Therapeutics Stock News

Healthcare > Biotechnology

Buy PSTV

*Your capital is at risk

$5.42

-0.0500 (-0.91%)

At Close: Jun 03, 2026

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

07:30am, Tuesday, 24'th Jun 2025

Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with t

Plus (PSTV) Upgraded to Buy: Here's Why

01:01pm, Thursday, 19'th Jun 2025

Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

06:26pm, Friday, 30'th May 2025

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

04:15pm, Friday, 30'th May 2025

Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasda

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

04:15pm, Friday, 23'rd May 2025

HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which in

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

11:00am, Wednesday, 14'th May 2025

Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

07:30am, Wednesday, 14'th May 2025

Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data pres

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

07:00am, Thursday, 08'th May 2025

HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platf

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

10:35am, Wednesday, 23'rd Apr 2025

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

08:00am, Wednesday, 23'rd Apr 2025

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pla

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

07:30am, Tuesday, 15'th Apr 2025

New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows prom

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by